Incidence of Long-term Post-acute Sequelae of SARS-CoV-2 Infection Related to Pain and Other Symptoms: A Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Background: Persistent symptoms are reported in patients who survive the initial stage of COVID-19, often referred to as "long COVID" or "post-acute sequelae of SARS-CoV-2 infection" (PASC); however, evidence on their incidence is still lacking, and symptoms relevant to pain are yet to be assessed.
Methods: A literature search was performed using the electronic databases PubMed, EMBASE, Scopus, and CHINAL and preprint servers MedRχiv and BioRχiv through January 15, 2021. The primary outcome was pain-related symptoms such as headache or myalgia. Secondary outcomes were symptoms relevant to pain (depression or muscle weakness) and symptoms frequently reported (anosmia and dyspnea). Incidence rates of symptoms were pooled using inverse variance methods with a DerSimonian-Laird random-effects model. The source of heterogeneity was explored using meta-regression, with follow-up period, age and sex as covariates.
Results: In total, 38 studies including 19,460 patients were eligible. Eight pain-related symptoms and 26 other symptoms were identified. The highest pooled incidence among pain-related symptoms was chest pain (17%, 95% confidence interval [CI], 11%-24%), followed by headache (16%, 95% CI, 9%-27%), arthralgia (13%, 95% CI, 7%-24%), neuralgia (12%, 95% CI, 3%-38%) and abdominal pain (11%, 95% CI, 7%-16%). The highest pooled incidence among other symptoms was fatigue (44%, 95% CI, 32%-57%), followed by insomnia (27%, 95% CI, 10%-55%), dyspnea (26%, 95% CI, 17%-38%), weakness (25%, 95% CI, 8%-56%) and anosmia (19%, 95% CI, 13%-27%). Substantial heterogeneity was identified (I2, 50-100%). Meta-regression analyses partially accounted for the source of heterogeneity, and yet, 53% of the symptoms remained unexplained.
Conclusions: The current meta-analysis may provide a complete picture of incidence in PASC. It remains unclear, however, whether post-COVID symptoms progress or regress over time or to what extent PASC are associated with age or sex.
Yanai H, Adachi H, Hakoshima M, Katsuyama H, Sako A Biomolecules. 2024; 14(8).
PMID: 39199353 PMC: 11352301. DOI: 10.3390/biom14080965.
Definitions and symptoms of the post-COVID syndrome: an updated systematic umbrella review.
Gutzeit J, Weiss M, Nurnberger C, Lemhofer C, Appel K, Pracht E Eur Arch Psychiatry Clin Neurosci. 2024; 275(1):129-140.
PMID: 39052056 PMC: 11799012. DOI: 10.1007/s00406-024-01868-y.
Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.
Seo J, Kim S, Kim Y, Kim E, Kim T, Kim T Infect Chemother. 2024; 56(1):122-157.
PMID: 38527781 PMC: 10990882. DOI: 10.3947/ic.2024.0024.
Fatigue outcomes following COVID-19: a systematic review and meta-analysis.
Poole-Wright K, Guennouni I, Sterry O, Evans R, Gaughran F, Chalder T BMJ Open. 2023; 13(4):e063969.
PMID: 37185637 PMC: 10151247. DOI: 10.1136/bmjopen-2022-063969.
Haunhorst S, Bloch W, Wagner H, Ellert C, Kruger K, Vilser D Oxf Open Immunol. 2023; 3(1):iqac006.
PMID: 36846561 PMC: 9494493. DOI: 10.1093/oxfimm/iqac006.